Breaking News

Financial Report: BASi

August 14, 2014

Service revenues up 14% in the quarter

BASi

3Q Revenues: $6.0 million (+8%)

3Q Earnings: $215,000 (-63%)

YTD Revenues: $18.2 million (+10%)

YTD Loss: $666,000 (earnings were $521 million YTD13)

Comments: Service revenue in the quarter increased 14% to $4.8 million primarily due to higher toxicology revenue, offset slightly by lower bioanalytical analysis revenue. Product revenue decreased 12% to $1.3 million. Earnings in the quarter and YTD were affected by non-cash decreases in the fair value of warrant liability of $66,000 and $1.1 million, respectively.

blog comments powered by Disqus
  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • A Biologic Innovator

    A Biologic Innovator's Pursuit to Uphold Patents

    Kristin Brooks, Contract Pharma||October 12, 2015
    Amgen v. Sandoz biosimilars litigation could impact the industry for years to come

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Four Pillars to Guide Your CRO Search

    Four Pillars to Guide Your CRO Search

    Alan Findlater , WIL Research||November 17, 2015
    Tips on how to seek out the best possible CRO-Sponsor relationship

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies